This is a demo store. No orders will be fulfilled.

Bevacizumab (anti-VEGF) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to VEGFA, >95%, high purity, Human IgG1, INHIBITOR of Vascular endothelial growth factor A inhibitor, INHIBITOR of Vascular endothelial growth factor A inhibitor

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Cynomolgus monkey,Human,Mouse
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
B411998
Grouped product items
SKU Size
Availability
Price Qty
B411998-100μg
100μg
4
$69.90
B411998-1mg
1mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$349.90
B411998-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$1,559.90
B411998-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,339.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Bevacizumab (anti-VEGF) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to VEGFA, >95%, high purity, Human IgG1, INHIBITOR of Vascular endothelial growth factor A inhibitor
Synonyms Recombinant Bevacizumab Antibody | rhuMab VEGF | Avastin | Anti-Human VEGF | Humanized Antibody | Bevacizumab (Anti-Human VEGF, Humanized Antibody) | Bevacizumab | EC 2.7.10.1 antibody | FLT 1 antibody | FLT antibody | Flt-1 antibody | FLT1 antibody | Fms
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity VEGFA
Application ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type INHIBITOR
Mechanism of action INHIBITOR of Vascular endothelial growth factor A inhibitor
Product Description

Bevacizumab is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Antibody Type Primary antibody
Clonality Recombinant
Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 26.5 kDa (Light Chain) & 51.7 kDa (Heavy Chain), under reducing conditions; 173.3 kDa, under non-reducing conditions.
Purification Method Protein A purified
Purity >95%
Source CHO supernatant
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 216974-75-3

Associated Targets(Human)

VEGFA Tclin Vascular endothelial growth factor A (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Bevacizumab (anti-VEGF) (B411998) - ELISA
Immobilized Recombinant Human VEGF Protein (rp155965) at 1 μg/mL can bind Bevacizumab (anti-VEGF) (B411998) with the EC50 of 4.16 ng/mL.

Bevacizumab (anti-VEGF) (B411998) - SEC
The purity of Bevacizumab (anti-VEGF) (B411998) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number Certificate Type Date Item
ZJ24F0202983 Certificate of Analysis Mar 01, 2024 B411998
ZJ23F0800853 Certificate of Analysis Aug 21, 2023 B411998
ZJ23F0800852 Certificate of Analysis Aug 21, 2023 B411998

Alternative Products

Citations of This Product

1. Wenjuan Huang, Liwen Wang, Ruhui Yang, Ronggui Hu, Qinxiang Zheng, Xingjie Zan.  (2022)  Combined delivery of small molecule and protein drugs as synergistic therapeutics for treating corneal neovascularization by a one-pot coassembly strategy.  Materials Today Bio,  17  (100456). 

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.